CD36 blockade exhibited promising prospects for cancer immunotherapy or combination therapy with anti-PD-1 through inhibiting TI-Treg accumulation and suppression without systemic loss of Treg number and function, thus preventing severe autoimmunity after treatment [147]. Here, PDCD1 is linked to cancer.